Table 1.
Baseline characteristics of studies included in the NMA.
| Author | Year | Design | No. pts | Tumor type | Disease location | RT schedule | CT schedule |
|---|---|---|---|---|---|---|---|
| Yang et al. (7) | 2018 | NCRT-S vs S | 451 | SCC | thoracic esophagus | 40Gy/2Gy/20f | two cycles vinorelbine 25mg/m2 d1,8 + cisplatin 75mg/m2 d1 q3w |
| von Dobeln et al. (9) | 2019 | NCRT-S vs NCT-S | 181 | AC, SCC | esophagus or GEJ | 40Gy/2Gy/20f | three cycles cisplatin 100mg/m2 d1 + fluorouracil 750mg/m2/d, d1–5 |
| Shapiro et al. (6) | 2015 | NCRT-S | 368 | AC, SCC, undifferentiated carcinoma | esophagus or GEJ | 41.4Gy/1.8Gy/23f | five cycles carboplatin AUC 2mg/mL/min d1, 8, 15, 22, 29 + paclitaxel 50mg/m2 d1, 8, 15, 22, 29 |
| Urba et al. (29) | 2001 | NCRT-S vs S | 100 | AC, SCC | esophasus | 45Gy/1.5Gy bid | cisplatin 20mg/m2/d d1-5,17-21 + fluorouracil 300mg/m2/d d1-21 + vinblastine 1mg/m2/d d1-4,17-20 |
| Stahl et al. (8) | 2017 | NCRT-S vs NCT-S | 119 | AC | GEJ | 30Gy/2Gy/15f | induction chemotherapy 14 weeks: 5-fluorouracil 2g/m2 qw + folinic acid 500mg/m2 qw + cisplatin 50mg/m2 q2w; concurrent chemotherapy 3 weeks: cisplatin 50 mg/m2 d2,8 + etoposide 80mg/m2 d3-5 |
| Xiao et al. (31) | 2003 | S-ART vs S | 495 | SCC | esophagus | 60Gy/30f, transpositioned stomach:50Gy/25f | NA |
| Law et al. (23) | 1997 | NCT-S vs S | 147 | SCC | thoracic esophagus | NA | two cycles cisplatin 100mg/m2 d1 + fluorouracil 500mg/m2/d d1–5 |
| Walsh et al. (30) | 1996 | NCRT-S vs S | 113 | AC | esophagus excluding cervical esophagus |
40Gy/15f | two cycles cisplatin 75 mg/m2 d7 + fluorouracil 15 mg/kg/d d1–5 |
| Zieren et al. (32) | 1995 | S-ART vs S | 68 | SCC | thoracic esophagus | 55.8Gy/1.8Gy/31f | NA |
| Tepper et al. (28) | 2008 | NCRT-S | 56 | AC, SCC | thoracic esophagus (below20cm) or GEJ | 50.4Gy/1.8Gy bid | cisplatin 100mg/m2/d + fluorouracil 1,000 mg/m2/d for 4 days on weeks 1 and 5 |
| Mariettte et al. (26) | 2014 | NCRT-S vs S | 195 | AC, SCC | thoracic esophagus | 45Gy/1.8Gy/25f | two cycles fluorouracil + cisplatin d1-5, 29-33 |
| Lee et al. (24) | 2004 | NCRT-S vs S | 101 | SCC | thoracic esophagus | 45.6Gy/1.2Gy/38f | cisplatin 60mg/m2 d1,22 + 5-fluorouracil 1000mg/m2 d2–5 (For patients with disease stable or responsive to CRT, three additional cycles of chemotherapy were given after surgery) |
| Lv et al. (25) | 2010 | NCRT-S vs S-ACRT vs S | 238 | SCC | thoracic esophagus | 40Gy/2Gy/20f | two cycles PTX 135mg/m2/d + DDP 20 mg/m2/d d1-3, 22-24 |
| Ancona et al. (12) | 2001 | NCT-S vs S | 94 | SCC | esophagus | NA | two cycles cisplatin 100mg/m2 d1, 21 + 5-fluorouracil 1000mg/m2 d1–5, 21-26 |
| Nygaard et al. (27) | 1992 | S vs NCT-S vs NRT-S vs NCRT-S | 186 | SCC | located at least 21 cm from the incisor teeth, or below the 5th thoracic vertebra | 35Gy/1.75Gy/20f | two cycles cisplatin 20mg/m2 d1-5 + bleomycin 5mg/m2 d1 |
| Allum et al. (11) | 2009 | NCT-S vs S | 802 | AC, SCC, undifferentiated carcinoma | esophagus or GEJ | NA | two cycles cisplatin 80mg/m2 d1 + fluorouracil 1000 mg/m2 daily as a continuous infusion over 96 hours q3w |
| Boonstra et al. (16) | 2011 | NCT-S vs S | 169 | SCC | thoracic esophagus | NA | two-four cycles cisplatin 80mg/m2 d1, etoposide 100 mg/m2 d1,2, followed by etoposide 200mg/m2 orally d3,5 q3w |
| Bosset et al. (17) | 1997 | NCRT-S vs S | 282 | SCC | thoracic esophagus | 37Gy/3.7Gy/10f | two cycles cisplatin 80mg/m2, d1-3 |
| Burmeister et al. (18) | 2005 | NCRT-S vs S | 256 | AC, SCC | thoracic esophagus | 35Gy/2.3Gy/15f | one cycle cisplatin 80mg/m2 d1+ fluorouracil 800mg/m2 d1–4 |
| Ando et al. (14) | 1997 | S-ACT vs S | 205 | SCC | thoracic esophagus | NA | two cycles cisplatin 70mg/m2 + vindesine 3mg/m2 d1, 21 |
| Ando et al. (15) | 2012 | S-ACT vs NCT-S | 330 | SCC | thoracic esophagus | NA | two cycles cisplatin 80mg/m2 d1+ 5-fluorouracil 800mg/m2 d1-5 |
| Ando et al. (13) | 2003 | S-ACT vs S | 242 | SCC | thoracic esophagus | NA | two cycles cisplatin 80mg/m2 d1 + fluorouracil 800mg/m2 d1-5 |
| Jeog (21) | 1993 | S-ART vs S-ACT | 258 | NA | cervical and thoracic esophagus | 50Gy/2Gy/25f | three cycles cisplatin 50mg/m2 + vindesine 3mg/m2 d1 |
| Kelsen et al. (22) | 2007 | NCT-S vs S | 243 | AC, SCC | esophagus or GEJ | NA | three cycles cisplatin 100mg/m2 d1 + 5-fluorouracil 100mg/m2 d1-5 |
| Burmeister et al. (19) | 2011 | NCT-S vs NCRT-S | 75 | AC | esophagus or GEJ | 35Gy/2.3Gy/15f | two cycles cisplatin 80mg/m2 d1 + 5-fluorouracil 1000mg/m2/d d1-5 q3w |
| Gignoux et al. (20) | 1987 | NRT-S vs S | 208 | SCC | thoracic esophagus | 33Gy/3.3Gy/10f | NA |
NCRT-S, neoadjuvant chemoradiotherapy followed by surgery; NCT-S, neoadjuvant chemotherapy followed by surgery; NRT-S, neoadjuvant radiotherapy followed by surgery; S, surgery; S-ACRT, surgery followed by adjuvant chemoradiotherapy; S-ACT, surgery followed by adjuvant chemotherapy; S-ART, surgery followed by adjuvant radiotherapy; SCC, squamous cell carcinoma; AC, adenocarcinoma; GEJ, gastroesophageal junction; qw, weekly; q2w, biweekly; q3w, every 3 weeks.